Premium
Intralesional Alpha Interferon Therapy in Papillary Superficial Transitional Cell Carcinoma of the Bladder A Pilot Study
Author(s) -
STASI S. M. DI,
VIRGILI G.,
VESPASIANI G.,
PORENA M.,
MICALI F.
Publication year - 1993
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1993.tb15985.x
Subject(s) - medicine , tolerability , alpha interferon , transitional cell carcinoma , pathological , urology , interferon alfa , gastroenterology , toxicity , progressive disease , surgery , chemotherapy , adverse effect , interferon , bladder cancer , immunology , cancer
Summary— The tolerability, toxicity and therapeutic efficacy of recombinant interferon alpha‐2a (rIFNα‐2a), administered by intralesional injection, were evaluated in 15 patients with papillary superficial transitional cell carcinoma of the bladder, rIFNα‐2a was delivered endoscopically in a single weekly dose of 3 × 10 6 IU for 4 weeks (total 12 × 10 6 IU). Transurethral resection of residual tumours was then performed. The response to treatment was assessed according to ultrasonographic, endoscopic and pathological findings. One patient achieved complete remission, 6 partial remission, 6 minor remission and 2 stabilisation of disease. All patients completed the course of treatment. A mild, transient, flu–like syndrome was documented after every injection. Immunological findings suggest that the antitumour effects of rIFNα2a are not mediated through the immune system.